| 冠心病降脂治疗新进展——Evinacumab |
| |
| 引用本文： | 王琦,邹云增.冠心病降脂治疗新进展——Evinacumab[J].金属学报,2022,27(4):362-364. |
| |
| 作者姓名： | 王琦 邹云增 |
| |
| 作者单位： | 1.复旦大学附属中山医院全科医学科，上海 200032；;2.复旦大学附属中山医院心血管病研究所，上海 200032 |
| |
| 摘 要： | 纯合子家族性高胆固醇血症（HoFH）是一种罕见的由于基因缺失导致的脂质代谢紊乱的疾病，传统的他汀类药物或者枯草溶菌素转化酶9（PCSK9）抑制剂降脂治疗效果不佳。Evinacumab针对这类患者，可以有效降低低密度脂蛋白胆固醇（LDL-C）水平。本文概述了Evinacumab的最新进展，汇总了Evinacumab的II期和III期临床试验研究结果，Evinacumab的副作用和其正在进行的相关临床试验，并介绍了Evinacumab的临床应用现状。
|
| 关 键 词： | 冠心病 Evinacumab 降血脂 新进展 |
New development of lipid-lowering therapy of coronary heart disease: Evinacumab |
| |
| WANG Qi,ZOU Yunzeng.New development of lipid-lowering therapy of coronary heart disease: Evinacumab[J].Acta Metallurgica Sinica,2022,27(4):362-364. |
| |
| Authors: | WANG Qi ZOU Yunzeng |
| |
| Affiliation: | 1.Department of General Medicine, Zhongshan Hospital of Fudan University, Shanghai 200032, China;2. Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai 200032, China |
| |
| Abstract: | Homozygous familial hypercholesterolemia is a rare genetic disorder of lipid metabolism, traditional lipid-lowering therapies such as statins and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have little efficacy in these patients. Evinacumab can reduce the levels of LDL-C effectively. In this review, we summarize the latest advances in Evinacumab, and review the phase 2 and phase 3 clinical trials results, adverse events, and the clinical trials results in progress of Evinacumab. Finally, we discuss the current status of Evinacumab in the clinical works. |
| |
| Keywords: | coronary heart disease Evinacumab lipid-lowering therapy the latest advances |
|
| 点击此处可从《金属学报》浏览原始摘要信息 |
|
点击此处可从《金属学报》下载全文 |
|
